Name: Monsanto Co. (NYSE:MON) | Income Statement (Quarterly)
Creator: Stock Analysis on Net

Income Statement
Quarterly Data

The income statement presents information on the financial results of a company business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.

Download chart

Monsanto Co., consolidated income statement (quarterly data)

US$ in millions

3 months ended:	Feb 28, 2018	Nov 30, 2017	Aug 31, 2017	May 31, 2017	Feb 28, 2017	Nov 30, 2016	Aug 31, 2016	May 31, 2016	Feb 29, 2016	Nov 30, 2015	Aug 31, 2015	May 31, 2015	Feb 28, 2015	Nov 30, 2014	Aug 31, 2014	May 31, 2014	Feb 28, 2014	Nov 30, 2013	Aug 31, 2013	May 31, 2013	Feb 28, 2013	Nov 30, 2012	Aug 31, 2012	May 31, 2012	Feb 29, 2012	Nov 30, 2011
Net sales	5,019)	2,658)	2,686)	4,230)	5,074)	2,650)	2,562)	4,189)	4,532)	2,219)	2,355)	4,579)	5,197)	2,870)	2,630)	4,250)	5,832)	3,143)	2,202)	4,248)	5,472)	2,939)	2,098)	4,219)	4,748)	2,439)
Cost of goods sold	(2,053)	(1,346)	(1,346)	(1,844)	(2,122)	(1,391)	(1,424)	(1,809)	(1,934)	(1,318)	(1,359)	(1,843)	(2,158)	(1,459)	(1,397)	(1,919)	(2,385)	(1,580)	(1,278)	(1,986)	(2,402)	(1,542)	(1,217)	(1,856)	(2,043)	(1,343)
Gross profit	2,966)	1,312)	1,340)	2,386)	2,952)	1,259)	1,138)	2,380)	2,598)	901)	996)	2,736)	3,039)	1,411)	1,233)	2,331)	3,447)	1,563)	924)	2,262)	3,070)	1,397)	881)	2,363)	2,705)	1,096)
Selling, general and administrative expenses	(652)	(664)	(938)	(789)	(657)	(585)	(975)	(729)	(586)	(543)	(741)	(718)	(647)	(580)	(905)	(655)	(625)	(589)	(778)	(632)	(598)	(542)	(709)	(638)	(543)	(500)
Research and development expenses	(394)	(382)	(439)	(417)	(381)	(370)	(421)	(387)	(340)	(364)	(422)	(374)	(372)	(412)	(485)	(427)	(404)	(409)	(435)	(392)	(360)	(346)	(438)	(375)	(353)	(351)
Restructuring charges	1)	(4)	6)	17)	(23)	36)	(7)	(15)	(9)	(266)	(393)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	10)	—)	—)	—)
Pending Bayer transaction related costs	(25)	(20)	(32)	(33)	(27)	(93)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)
Operating expenses	(1,070)	(1,070)	(1,403)	(1,222)	(1,088)	(1,012)	(1,403)	(1,131)	(935)	(1,173)	(1,556)	(1,092)	(1,019)	(992)	(1,390)	(1,082)	(1,029)	(998)	(1,213)	(1,024)	(958)	(888)	(1,137)	(1,013)	(896)	(851)
Income (loss) from operations	1,896)	242)	(63)	1,164)	1,864)	247)	(265)	1,249)	1,663)	(272)	(560)	1,644)	2,020)	419)	(157)	1,249)	2,418)	565)	(289)	1,238)	2,112)	509)	(256)	1,350)	1,809)	245)
Interest expense	(105)	(124)	(114)	(100)	(102)	(136)	(104)	(100)	(103)	(129)	(130)	(96)	(92)	(115)	(113)	(42)	(40)	(53)	(49)	(37)	(35)	(51)	(52)	(39)	(47)	(53)
Interest income	24)	15)	23)	17)	18)	18)	23)	14)	17)	20)	21)	18)	28)	38)	38)	17)	23)	24)	23)	19)	27)	23)	18)	21)	20)	18)
Other income (expense), net	24)	97)	9)	(4)	88)	(43)	138)	35)	(170)	(25)	(15)	(10)	6)	(15)	(18)	(3)	(61)	(20)	(26)	4)	(22)	(17)	—)	(3)	(37)	(6)
Income (loss) from continuing operations before income taxes	1,839)	230)	(145)	1,077)	1,868)	86)	(208)	1,198)	1,407)	(406)	(684)	1,556)	1,962)	327)	(250)	1,221)	2,340)	516)	(341)	1,224)	2,082)	464)	(290)	1,329)	1,745)	204)
Income tax (provision) benefit	(381)	(60)	170)	(230)	(505)	(61)	1)	(483)	(350)	137)	187)	(401)	(550)	(100)	87)	(341)	(672)	(152)	102)	(292)	(603)	(122)	70)	(361)	(540)	(70)
Income (loss) from continuing operations including portion attributable to noncontrolling interest	1,458)	170)	25)	847)	1,363)	25)	(207)	715)	1,057)	(269)	(497)	1,155)	1,412)	227)	(163)	880)	1,668)	364)	(239)	932)	1,479)	342)	(220)	968)	1,205)	134)
Income (loss) from discontinued operations	2)	1)	—)	—)	3)	10)	2)	—)	3)	12)	5)	—)	7)	16)	—)	—)	4)	9)	—)	—)	4)	7)	1)	(2)	7)	—)
Net income (loss)	1,460)	171)	25)	847)	1,366)	35)	(205)	715)	1,060)	(257)	(492)	1,155)	1,419)	243)	(163)	880)	1,672)	373)	(239)	932)	1,483)	349)	(219)	966)	1,212)	134)
Net (income) loss attributable to noncontrolling interest	(1)	(2)	(5)	(4)	2)	(6)	14)	2)	3)	4)	(3)	(14)	6)	—)	7)	(22)	(2)	(5)	(10)	(23)	—)	(10)	(10)	(29)	(1)	(8)
Net income (loss) attributable to Monsanto Company	1,459)	169)	20)	843)	1,368)	29)	(191)	717)	1,063)	(253)	(495)	1,141)	1,425)	243)	(156)	858)	1,670)	368)	(249)	909)	1,483)	339)	(229)	937)	1,211)	126)

The financial performance exhibits a pronounced cyclical pattern, with revenue and profitability fluctuating significantly across quarters. This seasonality is consistent throughout the period from late 2011 to early 2018, characterized by substantial peaks in the February and May quarters and troughs in the August and November quarters.

Revenue and Gross Profit Trends: Net sales demonstrate a recurring annual cycle, typically peaking between US$ 4.7 billion and US$ 5.8 billion in the second and third quarters of the calendar year, while declining to between US$ 2.1 billion and US$ 3.1 billion in the fourth and first quarters. Gross profit follows this same trajectory, reflecting a stable relationship between sales and the cost of goods sold. Despite the volatility, the gross margin remains robust, though the absolute peaks in net sales observed in 2014 slightly declined by 2017.
Operating Expense Analysis: Selling, general and administrative (SG&A) expenses and research and development (R&D) costs remain relatively stable compared to the volatility of revenue. SG&A expenses generally range between US$ 500 million and US$ 975 million, while R&D spending consistently fluctuates between US$ 340 million and US$ 485 million. A notable shift occurs starting in 2015, where restructuring charges and costs related to the Bayer transaction began to impact operating expenses, introducing additional non-recurring outflows that pressured operating income.
Operating Income and Profitability: Income from operations is subject to extreme swings, frequently alternating between significant quarterly profits exceeding US$ 2 billion and operating losses. The most significant volatility is observed in the periods ending August and November, where the company often records negative operating income. Net income attributable to the company mirrors this volatility, with peaks typically occurring in February and troughs in August.
Financial Costs and Other Income: Interest expenses show a clear upward trend over the analyzed period. Expenses that averaged approximately US$ 40 million to US$ 50 million per quarter between 2011 and 2013 increased to a range of US$ 100 million to US$ 136 million per quarter from 2014 through 2017. This indicates a significant increase in the company's debt burden or interest rate exposure over time. Other income and expenses remained volatile, with occasional spikes in 2016 and 2017 that provided temporary offsets to operating losses.
Net Income and Tax Impact: The bottom line is heavily influenced by the timing of tax provisions and benefits. During quarters of high profitability, income tax provisions are substantial, whereas tax benefits are often realized during quarters of operating losses. The net income attributable to the company reflects the culmination of these seasonal sales peaks, increasing interest costs, and the impact of one-time transaction and restructuring charges in the latter half of the data set.

AI Ask an analyst for more

My previous chats

Add tokens

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?

Monsanto Co. (NYSE:MON)

Income StatementQuarterly Data

Income Statement
Quarterly Data